Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
Risk-Benefit Analysis Advised Prior To Hormone Therapy
This article is from
The Cancer Letter
archive.
Vol. 33 No. 8 | August 27, 2010
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
QOL With Femara Comparable To Placebo, Analysis Finds
December 26, 2003
TCL Archive
James Doroshow Named NCI Deputy Director, Clinical Research
June 10, 2011
TCL Archive
House Bill Gives NCI $48 Mil. Less Than Clinton Requested
July 8, 1994
TCL Archive
OMB Reprogramming Ban Criticized
September 20, 1985
TCL Archive
Three-Quarters of P01 $$ Goes To Translational Grants, NCI Finds
October 2, 1992
TCL Archive
Lombardi Recruits Adams-Campbell.
October 3, 2008